ABBV Jan 2025 105.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:24AM EDT. Market open.
Loading interactive chart…
- Zacks
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day.
- Simply Wall St.
Boasting A 69% Return On Equity, Is AbbVie Inc. (NYSE:ABBV) A Top Quality Stock?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- PR Newswire
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
AbbVie (NYSE: ABBV) today announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 inhibitor. These moderate to severe plaque psoriasis patients previously had a suboptimal response to treatment with secukinumab or ixekizumab, both IL-17A inhibitor therapies, for at least six months before switching to risankizumab. The data were presented
© 2023 Yahoo. All rights reserved.
